COLL (Collegium Pharma) Gross Sales Margin

The gross profit margin of Collegium Pharmaceutical (COLL) demonstrates scaling efficiency through the distribution of niche analgesics via a unified sales force, while the 59.00 parameter determines the metric's magnitude. Collegium Pharmaceutical (COLL) generates revenue by supplying protected drugs to specialized clinics, relying on a strategy of aggressive acquisition of approved molecules for their subsequent integration into its own ecosystem.
Comprehensive metric breakdowns and analytics for Collegium Pharmaceutical (COLL)

This indicator measures direct production efficiency by determining the share of profit after deducting variable costs from total sales. The gross margin trend reflects the ability of Collegium Pharmaceutical (COLL) to maintain high product premiumization, which is ensured by strict patent control over drug protection technologies and limited competitor access to the strictly regulated analgesics market under FDA and DEA supervision.